Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2235-2244

  Torres, Cristian G ^a   Olivares, Araceli ^b   Stoore, Caroll ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

Canine mammary cancer; CD24; CD44; CF41.Mg cells; Simvastatin; Spheres

Indexed keywords

BETA CATENIN; CASPASE 3; CASPASE 7; CD133 ANTIGEN; CD24 ANTIGEN; DOXORUBICIN; GERANYLGERANYL PYROPHOSPHATE; HERMES ANTIGEN; PACLITAXEL; PROTEIN P53; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL CELL; ANIMAL VENEREAL TUMOR; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CARCINOMA CELL LINE; CELL INVASION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOG DISEASE; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; CELL PROLIFERATION; DOG; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL LINE; TUNEL ASSAY; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOG DISEASES; DOGS; FEMALE; FLOW CYTOMETRY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; IN VITRO TECHNIQUES; MAMMARY NEOPLASMS, ANIMAL; NEOPLASTIC STEM CELLS; SIMVASTATIN; SPHEROIDS, CELLULAR;

EID: 84927142880     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3850     Document Type: Article

References (47)

1. Torres CG, Pino AM and Sierralta WD: A cyclized peptide derived from α-fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells. Oncol Rep 21:1397-1404, 2009.
2. Paoloni M and Khanna C: Translation of new cancer treatment from pets dogs to humans. Nat Rev Cancer 8:147-156, 2008.
3. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S and Withrow S: The dog as a cancer model. Nat Biotechnol 24:1065-1066, 2006.
4. Sorenmo KU, Rasotto R, Zappulli V and Goldschmidt MH: Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Vet Pathol 48:85-97, 2011.
5. Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gartner F and Gruber AD: Molecular carcinogenesis of canine mammary tumors: news from an old disease. Vet Pathol 48:98-116, 2011.
6. Rivera P and von Euler H: Molecular biological aspects on canine and human mammary tumors. Vet Pathol 48:132-146, 2011.
7. Michishita M, Akiyoshi R, Yoshimura H, Katsumoto T, Ichikawa H, Ohkusu-Tsukada K, Nakagawa T, Sasaki N and Takahashi K: Characterization of spheres derived from canine mammary gland adenocarcinoma cell lines. Res Vet Sci 91:254-260, 2011.
8. Cocola C, Anastasi P, Astigiano S, Piscitelli E, Pelucchi P, Vilardo L, Bertoli G, Beccaglia M, Veronesi MC, Sanzone S, Barbieri O, Reinbold RA, Luvoni GC and Zucchi I: Isolation of canine mammary cells with stem cell properties and tumour-initiating potential. Reprod Domest Anim 44(Suppl 2):S214-S217, 2009.
9. Pang LY and Argyle D: Cancer stem cells and telomerase as potential biomarkers in veterinary oncology. Vet J 185:15-22, 2010.
10. Pang LY, Cervantes-Arias A, Else RW and Argyle DJ: Canine mammary cancer stem cells are radio- and chemo-resistant and exhibit an epithelial-mesenchymal transition phenotype. Cancers 3:1744-1762, 2011.
11. Blacking TM, Waterfall M, Samuel K and Argyle DJ: Flow cytometric techniques for detection of candidate cancer stem cell subpopulations in canine tumour models. Vet Comp Oncol 10:252-273, 2012.
12. Boudreau DM, Yu O and Johnson J: Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9:603-621, 2010.
13. Behbod F and Rosen JM: Will cancer stem cells provide new therapeutic targets? Carcinogenesis 26:703-711, 2005.
14. Demierre MF, Higgins PDR, Gruber SB, Hawk E and Lippman SM: Statins and cancer prevention. Nat Rev Cancer 5:930-942, 2005.
15. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehne F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S and Benz CC: Breast cancer growth prevention by statins. Cancer Res 66:8707-8714, 2006.
16. Taylor ML, Wells BJ and Smolak MJ: Statins and cancer: a metaanalysis of case-control studies. Eur J Cancer Prev 17:259-268, 2008.
17. Muck AO, Seeger H and Wallwiener D: Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 42:695-700, 2004.
18. Kusama T, Mukai M, Tatsuta M, Nakamura H and Inoue M: Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. Int J Oncol 29:217-223, 2006.
19. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG and Ghosh-Choudhury N: Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 286:11314-11327, 2011.
20. Borgquist S, Djerbi S, Ponten F, Anagtosnaki L, Goldman M, Gaber A, Manjer J, Landberg B and Jirstrom K: HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer 123:1146-1153, 2008.
21. WAF1/CIP1 pathway: Analyses using a breast cancer cell line and tumoral xenograft model. Int J Oncol 33:555-563, 2008.
22. Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J, Carvajal J, Gejman R, Owen GI and Cuello M: Lipophilic but not hydrophilic statins selectively induce cell death in gynecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med 14:1180-1193, 2010.
23. Kumar AS, Benz CC, Shim V, Minami CA, Moore DA and Esserman LJ: Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 17:1028-1033, 2008.
24. Herrero-Martin G and Lopez-Rivas A: Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins. FEBS Lett 582:2589-2594, 2008.
25. Kang S, Kim ES and Moon A: Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep 21:1317-1322, 2009.
26. Gopalan A, Yu W, Sanders BG and Kline K: Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and γ-tocotrienol. Cancer Lett 328:285-296, 2013.
27. Gauthaman K, Manasi N and Bongso A: Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol 157:962-973, 2009.
28. Geng SQ, Alexandrou AT and Li JJ: Breast cancer stem cells: multiple capacities in tumor metastasis. Cancer Lett 349:1-7, 2014.
29. Lorico A and Rappa G: Phenotypic heterogeneity of breast cancer stem cells. J Oncol 2011:135039, 2011.
30. Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR, Brown MP and Khanna KK: Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32:650-658, 2011.
31. Cruz MH, Sidén A, Calaf GM, Delwar ZM and Yakisich JS: The stemness phenotype model. ISRN Oncol 2012:392647, 2012.
32. Tang DG: Understanding cancer stem cell heterogeneity and plasticity. Cell Res 22:457-472, 2012.
33. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC and Dirks PB: Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806-823, 2009.
34. Geng SQ, Alexandrou AT and Li JJ: Breast cancer stem cells: multiple capacities in tumor metastasis. Cancer Lett 349:1-7, 2014.
35. Yang G, Xue F and Chen X: Prognostic value of different amounts of cancer stem cells in different molecular subtypes of breast cancer. Gland Surg 1:20-24, 2012.
36. - phenotype in canine mammary neoplasms. BMC Vet Res 9:205, 2013.
37. Pérez-Hernández AI, Catalán V, Gómez-Ambrosi J, Rodríguez A and Frühbeck G: Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol 5:65, 2014.
38. Tanabe A, Deguchi T, Sato T, Nemoto Y, Maruo T, Madarame H, Shida T, Naya Y, Ogihara K and Sahara H: Radioresistance of cancer stem-like cell derived from canine tumours. Vet Comp Oncol: Jul 28, 2014 (Epub ahead of print). doi:10.1111/vco.12110.
39. Li J and Zhou BP: Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 11:49, 2011.
40. Roarty K and Rosen JM: Wnt and mammary stem cells: hormones cannot fly wingless. Curr Opin Pharmacol 10:643-649, 2010.
41. Torres CG, Ramírez ME, Cruz P, Epuñan MJ, Valladares L and Sierralta WD: 27-Hydroxycholesterol induces the transition of MCF7 cells into a mesenchymal phenotype. Oncol Rep 26:389-397, 2011.
42. Wang N, Wang Z, Peng C, You J, Shen J, Han S and Chen J: Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling. Carcinogenesis 35:2544-2554, 2014.
43. Wang Z, Wang N, Li W, Liu P, Chen Q, Situ H, Zhong S, Guo L, Lin Y, Shen J and Chen J: Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway. Carcinogenesis 35:2346-2356, 2014.
44. Zafarana G and Bristow RG: Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie! Breast Cancer Res 12:111, 2010.
45. Guterres FA, Martinez GR, Rocha ME and Winnischofer SM: Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway. Exp Cell Res 319:2977-2988, 2013.
46. Wang Y, Xu SL, Wu YZ, Zao MS, Xu WJ, Yang HY and Li YX: Simvastatin induces caspase-dependent apoptosis and activates P53 in OCM-1 cells. Exp Eye Res 113:128-134, 2013.
47. Zanfardino M, Spampanato C, De Cicco R, Buommino E, De Filippis A, Baiano S, Barra A and Morelli F: Simvastatin reduces melanoma progression in a murine model. Int J Oncol 43:1763-1770, 2013.